The experimental data of pharmacodynamics can be clinical experimental data or animal experimental data, as long as it is proved that it has corresponding therapeutic and preventive effects, and it is not necessary to wait until the clinical experimental data comes out before applying for a patent. The specification of the patent application of the present invention has already disclosed the relevant animal experimental data, which basically meets the requirements for full disclosure of the specification.
Extended data:
Precautions:
China National Intellectual Property Administration gives priority to all kinds of patent applications or cases related to the prevention and treatment of COVID-19, such as protective articles and methods such as drugs and vaccines, detection methods and instruments, masks, goggles and disinfectants. Treatment and prevention in COVID-19.
This patent application relates to the epidemic prevention and control technology in COVID-19, which belongs to the situation that can be given priority examination as stipulated in the Measures for the Administration of Priority Examination of Patents, and also conforms to the relevant provisions of Article 10 on resumption of work and production. After the applicant puts forward the priority review request, China National Intellectual Property Administration considers that it meets the priority review standard and shall handle it according to the priority review procedure.
Baidu Encyclopedia-novel coronavirus Vaccine
People's Daily Online-China's first COVID-19 vaccine patent was approved.